- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04969731
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
November 18, 2021 updated by: GC Cell Corporation
An Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Immuncell-LC Therapy Combined With Gemcitabine Versus Adjuvant Gemcitabine Single Therapy After Resection in Patients With Pancreatic Ductal Adenocarcinoma
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Open-label, Randomized, Multi-center, Parallel, Phase III Clinical Trial
Study Type
Interventional
Enrollment (Anticipated)
408
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Daehak-ro, Jongno-gu
-
Seoul, Daehak-ro, Jongno-gu, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- Site Public Contact
- Phone Number: 82-02-2072-0694
- Email: snuhirb@gmail.com
-
Principal Investigator:
- Sang Hyub Lee
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age >/=20 years old, </=80 years old.
Histologically or cytologically confirmed pancreatic ductal adenocarcinoma that fulfill the following requirements:
- Participants have undergone a radical full resection (R0) or boundary resection (R1) operation and has elapsed at least two weeks after the resection based on the baseline, up to 12 weeks.
- Noncancerous ascites.
- No evidence of distant metastasis (such as liver, peritoneum)
- No evidence of distant metastasis in other distant abdominal or extra-abdominal organs
- Scheduled to be given gemcitabine alone as postoperative adjuvant chemotherapy
- Eastern Cooperative Oncology Group-performance status (ECOG-PS) 0 - 2
- Life expectancy is at least 12 weeks.
Adequate organ and marrow function at the screening and baseline as defined below:
- Absolute neutrophil count ≥ 1,500/μL
- Hemoglobin level ≥ 9 g/dL
- Platelet count ≥ 100,000/μL
- BUN, serum creatinine ≤ 1.5 × institutional upper limit of normal (ULN)
- AST, ALT ≤ 2.5 × institutional upper limit of normal (ULN)
- PT (INR), activated partial thromboplastin time (aPTT) ≤ 1.5 × institutional upper limit of normal (ULN)
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Received anticancer therapy including chemotherapy, biological therapy, immunotherapy, hormone therapy, radiation therapy, and other anti-cancer treatments. Note: Neo-adjuvant therapy for pancreatic cancer is allowed.
- Measurable lesions identified in the pancreas after surgery.
Known history at the screening as defined below.
- Confirmed cases of acquired immunodeficiency, which can be exacerbated by immunotherapy.
- History of autoimmune diseases that can be exacerbated by immunotherapy. (e.g. rheumatoid arthritis, systemic lupus, vascular inflammation, multiple sclerosis, adolescent-induced insulin-dependent diabetes, T-cell lymphoma, etc.)
- Active hepatitis B or hepatitis C virus infection confirmed.
- Human immunodeficiency virus (HIV) antibody test results are positive during screening
- History of malignant tumors other than pancreatic cancer within five years of screening. Note: skin basal cell cancer/squamous cell cancer, local prostate cancer, thyroid papillary cancer or cervical epithelial cancer can be participated even if 5 years have passed since successful treatment.
Known associated disease at the screening as defined below.
- Severe nephropathy: estimated glomerular filtration rate (eGFR)‡ <30 mL/min/1.73 m2
- Chest X-ray shows epileptic pneumonia or pulmonary fibrosis with clear, clinical symptoms.
- Severe infections or other uncontrolled active infectious diseases requiring the administration of antibiotics, antibacterial drugs, antifungal drugs, antiviral drugs, etc. that may affect safety and validity evaluation during clinical trials, as determined by the tester.
- Holder of thromboembolic disease or bleeding diatheses
- Those who are deemed unfit to participate in clinical trials because they are not controlled or require treatment (e.g., heart disease, pulmonary dysfunction, renal dysfunction, low blood pressure, hypertension, bone marrow inhibition, liver metastasis, hepatitis, history of alcoholism, myocardial infarction, etc.)
- Received Immuncell-LC, Natural Killer (NK) cell therapy or other cell therapy drugs within three years prior to screening.
- Anaphylaxis to the main ingredient or sub-brothers of Immuncell-LC or Gemcitabine
- Patients who cannot collect blood for manufacturing Immuncell-LC depending on the investigator's judgment.
- Pregnant or lactating women
- Fertility women and men who are not willing to use appropriate contraception from screening to 24 weeks after final administration of Immuncell-LC and/or Gemgitabine
- Received or applied with another investigational products or investigational device within 4 weeks prior to signing a written informed consent document.
- Patients who are inappropriate or impossible to participate in the trial due to non-recovery of resection or prior chemotherapy depending on the investigator's judgment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Immuncell-LC/Gemcitabine
Patients will receive 6 cycles Gemcitabine (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle) and Immuncell-LC 16 times during 60 weeks (4 treatments once a week, followed by 4 treatments every other week, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks)
|
IV
IV
Other Names:
|
ACTIVE_COMPARATOR: Gemcitabine
Patients will receive 6 cycles Gemcitabine alone (1000 mg/m2 on Days 1, 8, 15, 28-day a cycle)
|
IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence free survival (RFS) by independent review
Time Frame: Up to approximately 36 months after Last Patient In
|
Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by independent reviewer
|
Up to approximately 36 months after Last Patient In
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to approximately 36 months after Last Patient In
|
Overall survival is defined as the time from randomization to death due to any cause.
|
Up to approximately 36 months after Last Patient In
|
Recurrence free survival (RFS) by investigator
Time Frame: Up to approximately 36 months after Last Patient In
|
Recurrence free survival is defined as the time from randomization to the date of the recurrence confirmed by investigator
|
Up to approximately 36 months after Last Patient In
|
Carbohydrate antigen 19-9 level
Time Frame: Up to approximately 36 months after Last Patient In
|
Carbohydrate antigen 19-9 level
|
Up to approximately 36 months after Last Patient In
|
Quality of Life (QoL) EORTC QLQ-C30
Time Frame: Up to approximately 36 months after Last Patient In
|
The QLQ-C30 is composed of both multi-item scales and single-item measures.
These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale.
All of the scales and single-item measures range in score from 0 to 100.
A higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.
|
Up to approximately 36 months after Last Patient In
|
Quality of Life (QoL) EORTC QLQ-PAN26
Time Frame: Up to approximately 36 months after Last Patient In
|
The module comprises 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes).
The answers range is the following: not at all - 1 point, a little - 2 points, quite a bit - 3 points, very much - 4 points.
Minimum score is 26, maximum is 106.
The higher total score represents the worse quality of life.
|
Up to approximately 36 months after Last Patient In
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sang Hyub Lee, Seoul National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 7, 2021
Primary Completion (ANTICIPATED)
December 1, 2026
Study Completion (ANTICIPATED)
June 1, 2027
Study Registration Dates
First Submitted
July 6, 2021
First Submitted That Met QC Criteria
July 18, 2021
First Posted (ACTUAL)
July 21, 2021
Study Record Updates
Last Update Posted (ACTUAL)
November 22, 2021
Last Update Submitted That Met QC Criteria
November 18, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
- ILC-P3-PAN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
SOFIERecruitingFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
Sohag UniversityCompletedPancreatic Adenocarcinoma
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Yung NAQueen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern HospitalRecruitingMuscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaHong Kong
-
Air Force Military Medical University, ChinaRecruiting